Philips unveils CT dose reduction package
Over the last several months, Philips has been dropping hints that the company would unveil at RSNA 2009 a high-powered technique for cutting CT dose. The company did not disappoint.
Over the last several months, Philips has been dropping hints that the company would unveil at RSNA 2009 a high-powered technique for cutting CT dose. The company did not disappoint, unveiling iDose, its proprietary version of iterative reconstruction. The new package will not be available, however, until the second half of 2010, at which time it will ship on newly built Brilliance iCT and 64-channel scanners. A field upgrade will also be available to the installed base.
Company executives say the new software can cut CT dose to patients by up to 80% under some conditions. It was designed to deliver images that have the same look as conventionally processed images whose data are acquired at a much higher dose. A new RapidView IR console enables reconstruction 20 times faster than current hardware, according to the company. Because iDose works in the background, it requires no special training.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
